Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ONCOLYTICS BIOTECH INCONCY · Entity 6721 | Director · Chief Executive Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ONCOLYTICS BIOTECH INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2036-06-01 | Direct | 755,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 755,000 · Balance 755,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | GrantStock Option · Derivative | 755,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-26-027084 · ownership.xml · derivative · entry 1 Kelly Jared · CIK 0002103581 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755,000 Underlying: Common Shares · 755,000 shares Expires 2036-06-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2 · derivative.exercise_date: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. Read SEC document |
| March 12, 2026 Filed Mar 13, 2026 12:00 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 5,050 | $0.96 | $4,848.00 |
DisclosureSEC source: 0001493152-26-009982 · ownership.xml · nonDerivative · entry 1 Kelly Jared · CIK 0002103581 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,050 Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 12:00 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 29,500 | $0.84 | $24,839.00 |
DisclosureSEC source: 0001493152-26-006545 · ownership.xml · nonDerivative · entry 2 Kelly Jared · CIK 0002103581 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 12:00 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 5,600 | $0.84 | $4,681.60 |
DisclosureSEC source: 0001493152-26-006545 · ownership.xml · nonDerivative · entry 1 Kelly Jared · CIK 0002103581 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.820 to $0.856, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.